Roberto Zajdenverg

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Joseph J. Eron, Benjamin Young, David A. Cooper et al. · The Lancet · 2010 · 312 citations

Switchmrk 1, Treatment And Prevention, Human Retrovirus +10

Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts

Mauro Schechter, Roberto Zajdenverg, Gisely Falco et al. · American Journal of Respiratory and Critical Care Medicine · 2006 · 137 citations

Primary Antiretroviral Drug Resistance among HIV Type 1-Infected Individuals in Brazil

Eduardo Sprinz, Eduardo Martins Netto, Maria Patelli Juliani Souza Lima et al. · AIDS Research and Human Retroviruses · 2009 · 55 citations · Full text

Treatment And Prevention, Neurovirology, São Paulo +12

Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study)

Estêvão Portela Nunes, Marília Santini de Oliveira, Mônica Merçon et al. · HIV Clinical Trials · 2009 · 51 citations · Full text

Predicting CD4 counts in HIV-infected Brazilian individuals: a model based on the World Health Organization staging system.

Mauro Schechter, Roberto Zajdenverg, L L Machado et al. · PubMed · 1994 · 40 citations

World Health Organization, Immunology, Computational Epidemiology +24